Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | HPGD | P15428 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | TOP1 | P11387 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | CKS1B | P61024 | 1/20 | 0.30 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.30 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19988518 | 0.92 | ALDH1A1 (0.39) | L3MBTL1KDM4EALDH1A1HPGDLMNA | |
| SCHEMBL21155414 | 0.91 | TOP2A (0.30) | — | |
| SCHEMBL19988497 | 0.91 | TOP2A (0.33) | KDM4EALDH1A1LMNAMAPTMEN1 | |
| SCHEMBL19988657 | 0.91 | ALDH1A1 (0.38) | L3MBTL1KDM4EALDH1A1HPGDLMNA | |
| SCHEMBL19988463 | 0.90 | ALDH1A1 (0.34) | L3MBTL1KDM4EALDH1A1HPGDLMNA | |
| SCHEMBL19988514 | 0.89 | ALDH1A1 (0.34) | L3MBTL1KDM4EALDH1A1HPGDLMNA | |
| SCHEMBL19988509 | 0.89 | PIK3CD (0.31) | — | |
| SCHEMBL19988447 | 0.88 | ALDH1A1 (0.39) | L3MBTL1KDM4EALDH1A1HPGDLMNA | |
| SCHEMBL19988658 | 0.87 | KRAS (0.36) | KDM4EALDH1A1 | |
| SCHEMBL19988445 | 0.86 | ALDH1A1 (0.35) | L3MBTL1KDM4EALDH1A1HPGDLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3512848-B1 | COMPOUNDS WITH CARBAZOLE STRUCTURES | MERCK PATENT GMBH (DE) | 2020-11-18 | — | — | EP | disclosed |
| US-20190214574-A1 | COMPOUNDS WITH CARBAZOLE STRUCTURES | MERCK PATENT GMBH (DE) | 2019-07-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190214574-A1 | COMPOUNDS WITH CARBAZOLE STRUCTURES | CYCS, CYP3A4, CYP2E1 | L3MBTL1 4160/4885KDM4E 2638/4885ALDH1A1 506/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.